Meeting
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
Authors
Christos Chouaid
Centre Hospitalier Intercommunal de Créteil, Créteil, France
Christos Chouaid , Gwo Fuang Ho , Yotsawaj Runglodvatana , Xian He , Christoph Matthias Ahlers , Debbie Pomponio , Trever Todd , Thao Dang , Jarushka Naidoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04736173
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9148)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9148
Abstract #
TPS9148
Poster Bd #
131b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.
First Author: Delvys Rodriguez-Abreu
Poster
2023 ASCO Annual Meeting
VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).
First Author: Alexander I. Spira
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
First Author: Mark A. Socinski